{
  "abstract": "Fangyan Zhou, Chengyao Zhu Department of Dermatology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, People’s Republic of ChinaCorrespondence: Chengyao Zhu, Department of Dermatology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, N1 Shangcheng Avenue, Yiwu, 322000, People’s Republic of China, Email 8015009@zju.edu.cnAbstract: Pemphigus, a common autoimmune bullous disorder, imposes a significant clinical and socioeconomic burden on affected individuals. In addition to corticosteroids and immunosuppressants, standard-dose rituximab is now widely used in clinical practice for the treatment of moderate-to-severe pemphigus. However, the optimal dosing strategy of rituximab for patients with a history of treated pulmonary tuberculosis remains unclear. Herein, we report a case of refractory pemphigus vulgaris with a history of treated tuberculosis, successfully managed with ultra-low-dose rituximab in combination with corticosteroids and immunosuppressants. During the 6-month follow-up, the Pemphigus Disease Area Index score continued to decrease.Keywords: rituximab, pemphigus vulgaris, autoimmune bullous diseases, pulmonary tuberculosis, autoimmunity",
  "abstract_shown": true,
  "affiliations": [
    "Department of Dermatology"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Zhou F"
    },
    {
      "affs": [
        0
      ],
      "name": "Zhu C"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/c6mbtbetzp127.bib",
  "cited_by": 0,
  "doi": null,
  "fulltext_url": "https://www.dovepress.com/ultra-low-dose-rituximab-for-the-treatment-of-refractory-pemphigus-vul-peer-reviewed-fulltext-article-CCID",
  "id": "c6mbtbetzp127",
  "issns": [
    "1178-7015"
  ],
  "landing_url": "https://www.dovepress.com/ultra-low-dose-rituximab-for-the-treatment-of-refractory-pemphigus-vul-peer-reviewed-fulltext-article-CCID",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RL1-803"
    ]
  ],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-08",
  "publisher": "Dove Medical Press",
  "ris": "https://research.draconitic.com/paper/c6mbtbetzp127.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T14:21:26Z",
      "native_id": "50c2056b6bbb49bc84a9baa6c57ec30f",
      "source": "doaj",
      "url": "https://www.dovepress.com/ultra-low-dose-rituximab-for-the-treatment-of-refractory-pemphigus-vul-peer-reviewed-fulltext-article-CCID"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "lcc:RL1-803",
      "subfield": "general"
    }
  ],
  "title": "Ultra-Low-Dose Rituximab for the Treatment of Refractory Pemphigus Vulgaris with a History of Treated Pulmonary Tuberculosis: A Case Report",
  "title_text": "Ultra-Low-Dose Rituximab for the Treatment of Refractory Pemphigus Vulgaris with a History of Treated Pulmonary Tuberculosis: A Case Report",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T14:21:26Z",
  "url": "https://research.draconitic.com/paper/c6mbtbetzp127",
  "venue": "Clinical, Cosmetic and Investigational Dermatology",
  "versions": []
}